Impact of HIV co-infection on hepatitis B prevention and control: a view from sub-Saharan Africa

Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections are both endemic in sub-Saharan Africa, warranting high priority efforts in prevention and control. In developed countries, both viruses are transmitted more or less at the same time, and primarily in teenagers and adults. Because the two viruses share major risk factors, a number of HIV-infected individuals will either have past exposure to, or be chronic carriers of HBV. In contrast, HBV is predominantly transmitted in childhood in sub-Saharan Africa; and the majority of inhabitants are already exposed to, or are chronic carriers of HBV by the time they become exposed to HIV for the first time. Nevertheless, there is frequent detection of HBV in HIV-infected individuals (and vice versa) in the region because both viruses are highly endemic. Although there is a limited number of data on the interaction of HIV and HBV in coinfected persons in the sub-Saharan region, reports from around the world have convincingly demonstrated that HIV co-infection can have a negative impact on the transmission, natural history, prevention and control, and treatment of HBV. The impact of HIV co-infection on HBV prevention and control includes, but is not limited to: increased prevalence of HBV in HIV-infected persons; increased HBV infectivity and transmission; accelerated need for HBV therapy due to rapid progression to active chronic hepatitis B; limitation in the choice of drugs (where possible, drugs causing cross-reactivity are avoided in highly active antiretroviral therapy (HAART) regimens until there is a need to treat both viral infections), particularly in the phase of expanding HAART programmes in the region; the need to perform HBV DNA testing in HBsAg-negative sera due to frequent detection of occult hepatitis B in HIV-co-infected persons; and finally, the need for administering additional hepatitis B vaccine doses and ascertaining levels of protective anti-HBs (antibodies against HBsAg) following hepatitis B vaccination.

[1]  R. Burnett.  Hepatitis B virus and human immunodeficiency virus co-infection: impact on transmission and natural history of disease , 2008 .

[2]  R. Burnett,et al.  Mutations associated with lamivudine‐resistance in therapy‐naïve hepatitis B virus (HBV) infected patients with and without HIV co‐infection: Implications for antiretroviral therapy in HBV and HIV co‐infected South African patients , 2007, Journal of medical virology.

[3]  C. Thio,et al.  Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. , 2007, The Lancet. Infectious diseases.

[4]  R. Burnett,et al.  High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  M. Opravil,et al.  Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[6]  P. Angus,et al.  Lamivudine-Resistant Hepatitis B Virus and Ongoing Lamivudine Therapy: Stop the Merry-Go-Round, It'S Time to get off! , 2004, Antiviral therapy.

[7]  B. Tehan,et al.  Comparisons of the Hbv and HIV Polymerase, and Antiviral Resistance Mutations , 2003, Antiviral therapy.

[8]  Ding‐Shinn Chen,et al.  Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. , 2003, Journal of hepatology.

[9]  N. Kamiya.  The mechanisms of action of antivirals against hepatitis B virus infection. , 2003, The Journal of antimicrobial chemotherapy.

[10]  M. Wulfsohn,et al.  Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV) , 2003 .

[11]  P. Karayiannis.  Hepatitis B virus: old, new and future approaches to antiviral treatment. , 2003, The Journal of antimicrobial chemotherapy.

[12]  S. Cassol,et al.  Molecular Characteristics of Human Immunodeficiency Virus Type 1 Subtype C Viruses from KwaZulu-Natal, South Africa: Implications for Vaccine and Antiretroviral Control Strategies , 2003, Journal of Virology.

[13]  J. Sasadeusz,et al.  Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  F. Kasolo,et al.  Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. , 2003, AIDS research and human retroviruses.

[15]  Mphahlele Mj,et al.  Detection of HBV DNA from serologically negative or 'silent' HBV infections--viral or host factors? , 2002 .

[16]  K. Hu.  Occult hepatitis B virus infection and its clinical implications , 2002, Journal of viral hepatitis.

[17]  F. Dabis,et al.  HIV-1/AIDS and maternal and child health in Africa , 2002, The Lancet.

[18]  L. Morris,et al.  HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. , 2002, AIDS research and human retroviruses.

[19]  C. Binquet,et al.  The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. , 2002, Journal of hepatology.

[20]  R. Chaisson,et al.  Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.

[21]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[22]  N. Blackburn,et al.  Universal immunization of infants with low doses of a low-cost, plasma-derived hepatitis B vaccine in South Africa. , 2002, Bulletin of the World Health Organization.

[23]  P. Venter,et al.  The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. , 2001, Vaccine.

[24]  H. Margolis,et al.  Serological pattern “anti‐HBc alone”: Report on a workshop , 2000, Journal of medical virology.

[25]  F. André,et al.  Hepatitis B epidemiology in Asia, the Middle East and Africa. , 2000, Vaccine.

[26]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[27]  H. Whittle,et al.  Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. , 1999, Vaccine.

[28]  D. Nokes,et al.  The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? , 1999, Vaccine.

[29]  S. Locarnini.  Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance , 1998, Hepatology.

[30]  D. Kocks,et al.  Immunogenicity of a low-cost hepatitis B vaccine in the South African Expanded Programme on Immunisation. , 1998, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[31]  M. Kew,et al.  Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. , 1996, Gut.

[32]  C. Kiire.  The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. , 1996, Gut.

[33]  H. Whittle,et al.  Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages , 1995, The Lancet.

[34]  H. Inskip,et al.  Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation , 1993, The Lancet.